About Twentyeight-Seven Therapeutics

Twentyeight-Seven Therapeutics develops small-molecule therapeutics that target dysregulated nucleic acid processes, specifically focusing on microRNAs that influence regulatory proteins. This approach aims to restore cellular homeostasis disrupted by diseases such as cancer and autoimmune disorders, enhancing treatment efficacy beyond traditional therapies.

```xml <problem> Many diseases, such as cancer and autoimmune disorders, are driven by dysregulation in nucleic acid processing and signaling, which disrupts cellular homeostasis. Traditional therapies that target single cellular pathways often have limited efficacy due to the complex and adaptive nature of these diseases. </problem> <solution> Redona (formerly Twentyeight-Seven Therapeutics) develops small-molecule therapeutics designed to restore cellular homeostasis by targeting dysregulated nucleic acid processes. Their approach focuses on modulating key enzymes involved in RNA splicing, RNA/DNA stability, sensing, replication, and repair. By addressing multiple hallmarks of cancer and autoimmune diseases simultaneously, Redona aims to create more robust and durable therapies compared to current standards of care. These therapeutics are designed to impact various cancer hallmarks, including evading growth suppressors, avoiding immune destruction, and deregulating cellular energetics. </solution> <features> - Small-molecule drugs targeting nucleic acid regulators - Focus on RNA splicing as a novel therapeutic target - Modulation of multiple cancer hallmarks simultaneously - Designed to overcome resistance mechanisms in cancer cells - Development of therapies for both cancer and autoimmune diseases </features> <target_audience> The primary target audience includes patients with cancer and autoimmune diseases, as well as pharmaceutical companies seeking innovative therapeutic approaches for these conditions. </target_audience> ```

What does Twentyeight-Seven Therapeutics do?

Where is Twentyeight-Seven Therapeutics located?

Twentyeight-Seven Therapeutics is based in Cambridge, United Kingdom.

When was Twentyeight-Seven Therapeutics founded?

Twentyeight-Seven Therapeutics was founded in 2016.

Location

Cambridge, United Kingdom

Founded

2016

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Twentyeight-Seven Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

twentyeight-seven.com

Founded 2016 – Cambridge, United Kingdom

Funding

No funding information available.

Team

No team information available.

Company Description

Problem

Many diseases, such as cancer and autoimmune disorders, are driven by dysregulation in nucleic acid processing and signaling, which disrupts cellular homeostasis. Traditional therapies that target single cellular pathways often have limited efficacy due to the complex and adaptive nature of these diseases.

Solution

Redona (formerly Twentyeight-Seven Therapeutics) develops small-molecule therapeutics designed to restore cellular homeostasis by targeting dysregulated nucleic acid processes. Their approach focuses on modulating key enzymes involved in RNA splicing, RNA/DNA stability, sensing, replication, and repair. By addressing multiple hallmarks of cancer and autoimmune diseases simultaneously, Redona aims to create more robust and durable therapies compared to current standards of care. These therapeutics are designed to impact various cancer hallmarks, including evading growth suppressors, avoiding immune destruction, and deregulating cellular energetics.

Features

Small-molecule drugs targeting nucleic acid regulators

Focus on RNA splicing as a novel therapeutic target

Modulation of multiple cancer hallmarks simultaneously

Designed to overcome resistance mechanisms in cancer cells

Development of therapies for both cancer and autoimmune diseases

Target Audience

The primary target audience includes patients with cancer and autoimmune diseases, as well as pharmaceutical companies seeking innovative therapeutic approaches for these conditions.